INTRODUCTION
The AhR is a member of the evolutionarily conserved Per/ARNT/SIM (PAS) family of transcription factors 1 . It is the only PAS family member known to be activated by endogenous or exogenous ligands. PAS proteins contribute to several important physiological processes 2 . Historically, the evolutionarily conserved AhR was studied in the For personal use only. on June 10, 2017. by guest www.bloodjournal.org From context of its activation by a variety of ubiquitous environmental pollutants including dioxins, polychlorinated biphenyls, and polycyclic aromatic hydrocarbons, and subsequent transactivation of cytochrome P450-encoding genes 3, 4 . However, the AhR field has recently undergone a major paradigm shift following the demonstration that the AhR plays important physiological roles in the absence of environmental ligands 3, 4 . For example, several studies demonstrate that the AhR contributes to regulation of autoimmune responses [5] [6] [7] [8] [9] [10] [11] , inflammation 9, 12 , cell growth 13 , cell migration 14, 15 , apoptosis 16, 17 and cancer progression [18] [19] [20] . Specifically with regard to hematopoietic cells, the AhR regulates development of Th 17 cells, regulatory T cell subsets, and gut-associated T cells [5] [6] [7] [8] [9] [10] 21 .
Importantly, recent breakthrough studies suggest that the AhR plays a critical role in nominal hematopoietic stem cell (HSC) growth and differentiation 22, 23 . For example, AhR -/mice are characterized by an increased number of bone marrow HSCs 22 and a commensurate increased propensity to develop lymphomas 24 . These insights led to the hypothesis that the AhR, activated by endogenous ligands, regulates stem cell growth and/or differentiation 25 . Despite these early results, little is known about the effects of AhR modulation on the development of megakaryocyte (Mk)-or erythroid-lineage cells from bipotential progenitors. Involvement of the AhR in this process is suggested by decreased numbers of erythrocytes and platelets in young AhR -/mice and the skewing of the blood cell repertoire towards myeloid and B lineage cells as AhR -/mice age 22, 26, 27 .
The differentiation of HSCs into all eight blood cell lineages is a critical and tightly regulated physiological process 28 . Disruption of this regulation can have a profound downstream effect on multiple hematopoietic cell types, potentially leading to a myriad of blood cell disorders ranging from leukemia to stem cell exhaustion 22, 29 . However, definition of the molecular mechanisms that control specification of primary human blood cells has been hampered by the lack of a model system in which sufficient numbers of stem or progenitor cells can be grown and the absence of practical and efficient techniques for directing differentiation of hematologic progenitors into end stage cells. For example, several teams have published proof-of-principle examples of the derivation of Mk- [30] [31] [32] and erythroidlineage cells 30, 32, 33 from embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC). However, development of a model system which results in robust expansion of For personal use only. on June 10, 2017. by guest www.bloodjournal.org From these cell populations or their immediate precursors and with which molecular signals driving cell differentiation can readily be studied has been problematic.
Our conceptual approach to addressing this need was to mimic in vitro the natural sequence of blood cell development in vivo to derive the number and range of cells types needed for the creation of a genetically tractable iPSC-based platform. Key components of this new platform, as shown here, include the definition of feeder cell-free, chemicallydefined conditions under which iPSCs can be differentiated into modest numbers of hematopoietic progenitor cells (HP) and a stimulus (aryl hydrocarbon receptor/AhR hyperactivation) which results in a dramatic expansion of this MEP (megakaryocyte-erythroid progenitor)-like population and the production of virtually unlimited numbers of Mk-and erythroid-lineage cells. Thus, this culture system allows for the efficient and consistent capture in culture and expansion of populations of HPs that exist only transiently during in vivo development of platelets and red blood cells (RBC). Furthermore, continued AhR manipulation, presumably in rapidly expanding MEP populations, dictates cell fate choices including the decision to differentiate into Mk-vs erythroid-lineage cells. In addition to demonstrating a critical and previously unappreciated role for the AhR in the hematopoietic progenitor cell, Mk, and erythroid lineages, the platform detailed here provides a flexible, consistent and genetically tractable system for studying blood cell differentiation at multiple defined stages of development. Since this system can be initiated from both normal and disease-specific iPSC, it is also amenable to the generation and study of Mk-and erythroidlineage cells from patients with blood diseases. Finally, this work represents a significant step towards the in vitro production of virtually unlimited numbers of therapeutic, patientspecific RBCs and platelets.
EXPERIMENTAL PROCEDURES
iPSC Derivation and Culture: iPSC derivation was achieved using the hSTEMCCA lentiviral vector as previously described 49 .
Directed Differentiation of iPSCs into Hematopoietic Cells: iPSCs were plated onto matrigel coated 6-well plates in iPSC media conditioned on iMEFs for 24 hours and For personal use only. on June 10, 2017. by guest www.bloodjournal.org From supplemented with 2 ng/ml Rho Kinase Inhibitor and 20 ng/ml bFGF. After two days, iPSC media was replaced with media cocktails designed to initiate hematopoietic specification:
D0-1 media: RPMI (Invitrogen A1049101) supplemented with 5ng/ml hBMP-4 (R&D 314-BP-010), 50ng/ml hVEGF (R&D 293-VE-010), 25ng/ml hWnt3a (R&D 287-TC-500) and 10% KOSR; D2 media: RPMI supplemented with 5ng/ml hBMP-4, 50ng/ml hVEGF, 20ng/ml bFGF and 10% KOSR; D3 media: StemPro 34 (Invitrogen 10639011), 5ng/ml hBMP-4, 50ng/ml hVEGF, and 20ng/ml bFGF; D4-5 media: StemPro 34, 15ng/ml hVEGF, and 5ng/ml bFGF; D6 media: 74% IMDM (Invitrogen 12330061), 24% Hams F12 (Mediatech 10-080-CV), 1% B27 supplement (Invitrogen 12587-010), 0.5% N2-supplement (Invitrogen 17502-048), 0.5% BSA (Sigma A3059), 50ng/ml hVEGF, 100ng/ml bFGF, 100 ng/ml hSCF (R&D 255-SC-010), 25ng/ml hFlt3 Ligand (R&D 308-FKN-005); D7 media: 74% IMDM, 24% Hams F12, 1% B27 supplement, 0.5% N2-supplement, 0.5% BSA, 50ng/ml hVEGF, 100ng/ml bFGF, 100ng/ml hSCF, 25ng/ml hFlt3 Ligand, 50ng/ml hTPO 
RESULTS

Analysis of human hematopoietic cell differentiation genomic mapping (dMap) data suggests a role for AhR in normal hematopoietic specification
As a guide for assessing the possible role of the AhR receptor in hematopoietic cells, we analyzed the "dMap" dataset (www.broadinstitute.org/dmap) 34 
The aryl hydrocarbon receptor (AhR) agonist 6-formylindolo[3,2-b]carbazole (FICZ) allows for the exponential expansion of iPSC-derived hematopoietic progenitor cells
The clinical translation of iPSC-based technologies will require many modifications to improve the efficiency of generation and the safety profile of iPSC-derived cells. Using a novel, feeder cell-free, chemically-defined system for the production of hematopoietic progenitor cells from human iPSCs that is not beholden to the use of stromal cell lines or xenogeneic agents, our primary goal was the production of large numbers of clinically relevant, high purity hematopoietic cells. Our approach follows the roadmap provided by For personal use only. on June 10, 2017. by guest www.bloodjournal.org From the developing embryo. Since ESC and iPSC resemble pluripotent, undifferentiated cells of the early blastocyst embryo, the signals active in the early embryo were harnessed to direct the differentiation of iPSC in vitro. Due to the known variability in the formation of human embryoid bodies 35 , this protocol utilizes a 2D culture system optimized to produce hematopoietic progenitor cells within 10-15 days ( Figure 1A) . Because of the expression of Ahr mRNA early in the MEP differentiation process ( Supplementary Figure 1) , a strong AhR agonist, FICZ, was added on Day 7. Figure 2B) . In comparison to undifferentiated iPSCs, these cells also significantly upregulated globin genes characteristic of erythroid-lineage cells and PF4, CD62P, and NFE2 genes characteristic of Mk-lineage cells ( Figure 1C) . Note that the timeframe to generate what phenotypically appear to be MEPs is significantly shorter than that noted in previously described protocols 31, 36 and that no fractionation or further manipulation of the cells is required. Importantly, maintenance of cultures in erythroid specification media containing EPO, or Mk specification media containing TPO, resulted in a final fate choice leading to the appearance of distinct populations of CD235 + /CD41erythroid-or CD41 + /CD235 -Mk-lineage cells respectively ( Figure 1D ). These results are consistent with the presence of functionally bipotential
MEPs.
A crucial roadblock in the translation of iPSC technology is the ability to produce sufficient, clinically relevant quantities of cells. Even for basic research studies, the numbers and For personal use only. on June 10, 2017. by guest www.bloodjournal.org From quality of hematopoietic cells that can be produced through the directed differentiation of iPSC can be limiting 37 . With the outgrowth of HPs by day 15 of culture, we were presented with the possibility that ongoing AhR activation could continue to drive progenitor expansion. Here, we demonstrate that the AhR agonist FICZ has the ability to allow for the exponential expansion of iPSC-derived hematopoietic progenitor cells. In comparison to untreated control samples, FICZ-treated HPs demonstrate significantly less cell death as judged by propidium iodide and Hoecsht dye exclusion as well as significantly more proliferation as judged by EdU (5-ethynyl-2'-deoxyuridine) incorporation (Figures 2A-D) .
Furthermore, in contrast to untreated cells in which 500,000 HPs yielded 4 million cells (8 fold increase), FICZ-treated day 15 HPs demonstrated logarithmic expansion such that FICZ treatment of 500,000 HPs yielded 300 million cells (600 fold increase) within 10 days ( Figure 2E ).
AhR mediates the expansion and specification of hematopoietic progenitors
The results presented above strongly suggest that AhR hyper-activation drives human HP expansion. To further test this hypothesis, AhR expression and functionality in both undifferentiated iPSCs and differentiated HPs were investigated. Little or no AhR receptor protein was detected in human iPSC by western blotting (Figure 3A) . However, a significant increase in expression of the prototypic AhR target gene, CYP1B1 was seen by qPCR 72 hrs after treatment with 0.2μM FICZ suggesting that iPSCs express AhR but at levels below those detectable in western blots ( Figure 3B) . Similarly, AhR protein was not detected in day 15 HPs. However, treatment of day 15 HPs with FICZ significantly induced CYP1B1 expression ( Figure 3B) . Similar data were obtained with two other AhR agonists, β-naphthoflavone (BNF) and the prototypic environmental AhR ligand, 2,3,7,8- Supplementary Figure 2) . In contrast to iPSCs or day 15 HPs, AhR was robustly expressed in day 30 and day 60 HPs ( Figure 3A) .
To quantify baseline AhR transcriptional activity, presumably enforced by an endogenous
AhR ligand, we cloned a human AhR-driven promoter 38 39 into a lentivirus reporter vector that encodes for dsRed and ZsGreen ( Figure 4A) . This dual gene AhR-driven reporter In contrast to the mock-infected HPs, the AhR-driven reporter-infected HPs displayed a modest increase in dsRed expression suggesting that the AhR responsive elements (AhREs) in the reporter were being transactivated in the HPs (Figure 4B ). An increase in the FICZ concentration to 0.4μM significantly increased DsRed expression ( Figure 4B) . These results are consistent with the induction of CYP1B1 expression in primary HPs after FICZ exposure ( Figure 3B) .
Importantly, a significant decrease in DsRed expression (below the level of expression in the mock-infected populations) was noted when the reporter virus-infected cells, maintained in a basal level of 0.2μM FICZ, were treated with 5μM of CH223191 ( Figure   4B ). Similar results were obtained using a lentivirus encoding an AhR-driven luciferase or green-fluorescent reporter (data not shown). These studies confirm the presence of a functional, FICZ-responsive AhR in human HPs.
In order to determine if FICZ-mediated transactivation of the AhR receptor was responsible for the exponential expansion of iPSC-derived HPs, the effect of AhR inhibition with CH223191 on cell viability and expansion of the HP population was tested. As previously shown in Figure 2 , addition of 0.2μM FICZ on day 7 of iPSC culture significantly increased the percentage of cells captured in the viable cell gate, as defined by forward and side scatter parameters (e.g., 15 .5% vs 8.09%) ( Figure 4C ). However, treatment with 5μM CH223191 one day prior to addition of FICZ completely blocked the increase in viable cells as measured either by forward and side scatter parameters or propidium iodide uptake (Figures 4C,D) . Furthermore, no significant expansion of HPs was seen in cultures treated with CH223191 plus FICZ (data not shown). These data indicate that AhR activation with For personal use only. on June 10, 2017. by guest www.bloodjournal.org From 1 FICZ mediates an increase in HP viability and drives expansion of HP populations. The efficacy of the CH223191 was confirmed by its ability to block CYP1B1 induction as assayed by qRT-PCR ( Figure 4E) .
Chronic AhR activation is permissive to erythroid cell maturation
Previous studies suggest that the AhR may play a critical role in hematopoietic cell development and function, possibly including the growth and differentiation of hematopoietic stem cells [7] [8] [9] 41 . Having shown that AhR activation results in exponential expansion of HP populations (Figure 2) , and that the presence of EPO or TPO and FICZ generates either erythroid-lineage or Mk-lineage cells in the short term (Figure 1D) Supplementary Figure 4A) . These results, as well as the lack of adult globin (β-globin) in this population suggest that iPSCderived erythroid-lineage cells are at an embryonic/fetal developmental stage.
AhR repression promotes megakaryocyte specification
As the default pathway in our system seemed to allow for the specification and maturation of iPSC-derived HPs into the red cell lineage under chronic AhR agonism, we hypothesized that AhR downregulation in these long-term cultures might allow for the emergence of an alternative lineage, megakaryocytes. To test this hypothesis, we evaluated the effects of AhR inhibition using ectopic expression of an AhR reporter plasmid previously shown to block human AhR transcriptional activity 42, 43 . We constructed and utilized a lentiviral vector that encoded an AhR repressor element (AhRR) along with a ZsGreen reporter ( Figure   6A ). This AhRR element potently and specifically inhibits either baseline or AhR agonistinduced AhR transcriptional activity 42, 43 . In contrast to cells transduced with a control ZsGreen reporter, cells infected with the AhRR-ZsGreen lentivirus and cultured for 5 days produce a significantly higher number of large, CD41 + Mk-lineage cells (Figure 6B and C) .
Interestingly, while the AhRR-transduced populations were capable of producing Mklineage cells, they also contained fewer CD235 + cells, suggesting that AhR antagonism initiates a transcriptional switch from erythroid to megakaryocyte lineage specification ( Figure 6C) .
To further study the Mk-lineage cells produced via AhR antagonism, a discontinuous BSA gradient (0, 1.5, 3%) was used to isolate mature Mks from AhRR-ZsGreen-transduced populations. In contrast to the ZsGreen-AhRRpopulation, the majority of the ZsGreen-AhRR + population was positive for a combination of two hallmark Mk lineage markers, CD41a and CD42b ( Figure 6D) . These cells also demonstrated hallmark characteristics of mature Mks including lobular nuclei and membrane blebbing at the surface of the cells ( Figure 7A ) and the ability to endoreplicate to 8N and 16N (Figure 7B) . Quantitative PCR analysis of these cells also revealed robust upregulation of a spectrum of Mk-related genes For personal use only. on June 10, 2017. by guest www.bloodjournal.org From including GPV, GPIIb, PF4, and CD62P ( Figure 7C) . Functionality of iPSC-derived Mks was assessed by their ability to produce platelets. Mature Mks were grown on an OP9 stromal layer for 3-5 days to allow for terminal Mk differentiation and platelet production.
Cultures were initially gated using GPIIb (CD41a) expression and demonstrated that iPSC Mk-derived platelets were similar to platelet populations from whole blood with respect to size (FSC), granularity (SSC), as well as the expression of GPIX and GP1b, two subunits of the GPIb/V/IX complex, that are characteristic of platelets ( Figure 7D) .
Collectively, these data suggest that production of erythroid-lineage cells is the default pathway of HPs chronically stimulated with an AhR ligand. Inhibition of that default pathway results in an increase in the percentage of Mk-lineage cells, an outcome that could reflect either a switch in cell fate decision to favor Mk production or the maintenance of a small population of Mks during a decrease in the production of AhR-dependent erythroid-lineage cells.
DISCUSSION
Our results indicate that AhR has a physiological and functional role in normal hematopoietic development and that modulation of the receptor in hematopoietic progenitor cells can direct cell fate. We demonstrate a novel methodology for the directed differentiation of pluripotent stem cells in serum-and feeder cell-free, chemically-defined culture conditions into HPs capable of final specification into Mk-and/or erythroid-lineage cells.
As a starting point for these studies, we utilized human hematopoietic cell differentiation genomic (dMap) array data as a roadmap for assessing the possible role of AhR in hematopoietic cells. These analyses suggested that the AhR plays an important role in blood cell development and were consistent with previous studies 22, 23, 26, 44 .
In our studies, we have found that the use of a non-toxic aryl hydrocarbon receptor agonist in a directed differentiation scheme dramatically increases the number of HPs and resultant cells. This is an important finding in that, traditionally, the evolutionarily conserved AhR has For personal use only. on June 10, 2017. by guest www.bloodjournal.org From been studied for its role in environmental chemical-induced toxicity, and in our system it is shown to be involved in the growth and the differentiation of at least two crucial blood cell types. Following the addition of the potent AhR ligand FICZ to our cultures, we observed exponential expansion of HPs from half a million to 300 million cells in ten days.
Importantly, the role of AhR in the HP population was confirmed using a highly specific AhR inhibitor. This logarithmic expansion of cells appears to be a function of decreased cell death and is consistent with previous studies, which suggest that the AhR can control apoptosis 16, 17 .
It is important to note that these results can be contrasted with work performed by Interestingly, FICZ, the AhR ligand utilized throughout this work, is a photometabolite of tryptophan originally described by the Rannugs 46 . Based on previous studies demonstrating the ubiquity of FICZ 47 and taken together with our data demonstrating the activity of this ligand, it is possible that FICZ plays a role in regulating hematopoiesis in vivo, possibly with other endogenous AhR ligands also playing a role. The ability to expand HPs with an AhR ligand also suggests that blood cell development may be affected by a variety of environmental ligands 26, 48 In addition to allowing for the exponential expansion of HPs, our results indicate that AhR modulation is also involved in the further specification of both the erythroid and Mk lineages with AhR agonism permissive to the differentiation of erythroblasts and antagonism or downregulation of AhR leading to Mk specification. Although erythropoietin (EPO) and thrombopoietin (TPO) are the major drivers in RBC and platelet development, AhR may play a cytokine-independent role in the development and specification of these lineages and warrants further study in this capacity.
For personal use only. on June 10, 2017. by guest www.bloodjournal.org From During the course of our studies, we derived putative progenitors known to express markers of both the Mk and erythroid lineages. A particularly striking outcome of our experiments is the development of a simple protocol for the rapid and highly efficient derivation of putative MEPs, which expand exponentially under AhR agonism. In addition to the ability to answer basic biological questions concerning hematopoietic development, a useful outcome for this work will be the utilization of this in vitro platform for the production of blood products as the combination of AhR modulation with a completely chemicallydefined and xenobiotic agent-free differentiation scheme makes Good Maufacturing Practice (GMP) production and clinical translation feasible. Blood transfusion is an indispensable cell therapy, and the safety and adequacy of the blood supply are of national and international concern. An iPSC-based system, such as the one described here in which large numbers of cells can be produced, could allow for red blood cell and platelet transfusion without problems related to immunogenicity, contamination, or supply. Furthermore, the ability to produce both populations of cells from a single source, and the fact that both platelets and mature RBCs contain no nuclear genetic material, may mitigate some safety concerns usually associated with suggestions to transfuse or transplant iPSCderived cells in humans. iPSC Mk-derived platelets. Mature Mks were grown on an OP9 stromal layer for 3-5 days to allow for terminal Mk differentiation and platelet production. Cultures were initially gated using GPIIb (CD41a) expression and demonstrated that iPSC Mk-derived platelets were similar to platelet populations from whole blood with respect to size (FSC), granularity (SSC), as well as the expression of GPIX and GP1b, two subunits of the GPIb/V/IX complex, that are characteristic of platelets.
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